Article Text

other Versions

PDF
Prognostic value of inappropriately high left ventricular mass in asymptomatic severe aortic stenosis
  1. Giovanni Cioffi1,
  2. Pompilio Faggiano2,
  3. Enrico Vizzardi3,
  4. Luigi Tarantini4,
  5. Dana Cramariuc5,
  6. Eva Gerdts5,
  7. Giovanni de Simone6
  1. 1Department of Cardiology, Villa Bianca Hospital, Trento, Italy
  2. 2Cardiology Unit, Spedali Civili, Brescia, Italy
  3. 3Department of Cardiology, University of Brescia, Brescia, Italy
  4. 4Department of Cardiology, Ospedale civile di Belluno, Belluno, Italy
  5. 5Department of Heart Disease, Haukeland University Hospital, and Institute of Medicine, University of Bergen, Bergen, Norway
  6. 6Department of Clinical and Experimental Medicine, Federico II, University Hospital, Naples, Italy
  1. Correspondence to Dr Giovanni Cioffi, Department of Cardiology, Villa Bianca Hospital; Via Piave 78, 38100 Trento, Italy; gcioffi{at}villabiancatrento.it

Abstract

Objectives In patients with aortic stenosis (AS) left ventricular (LV) myocardial growth may exceed individual needs to compensate LV haemodynamic load leading to inappropriately high LV mass (iLVM), a condition at high risk of adverse cardiovascular events. The prognostic impact of iLVM was determined in 218 patients with asymptomatic severe AS.

Methods iLVM was recognised when the measured LV mass exceeded 10% of the expected value predicted from height, sex and stroke work (prognostic cut-off assessed by a specific ROC analysis). For assessment of outcome, the endpoint was defined as death from all causes, aortic valve replacement or hospital admission for non-fatal myocardial infarction and/or congestive heart failure.

Results At the end of follow-up (22±13 months) complete clinical data were available for 209 participants (mean age 75±11 years). A clinical event occurred in 81 of 121 patients (67%) with iLVM and in 26 of 88 patients (30%) with appropriate LV mass (aLVM) (p<0.001). Event-free survival in patients with aLVM and iLVM was 78% vs 56% at 1-year, 68% vs 29% at 3-year and 56% vs 10% at 5-year follow-up, respectively (all p<0.01). Cox analysis identified iLVM as a strong predictor of adverse outcome (Exp β 3.08; CI 1.65 to 5.73) independent of diabetes, transaortic valve peak gradient and extent of valvular calcification. Among patients with LV hypertrophy, those with iLVM had a risk of adverse events 4.5-fold higher than counterparts with aLVM.

Conclusions iLVM is common in patients with asymptomatic severe AS and is associated with an increased rate of cardiovascular events independent of other prognostic covariates.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval The protocol of the present study was approved by the local institutional review boards.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles